Methods
At our institution, LVAD implantation program for eligible patients with heart failure was started in year 2017. During the period from 2017 to 2019, the overall number of patients submitted to LVAD implantation using Heartmate3 was 28 patients, and 4 of them (14.3%) had sickle-cell trait (SCT) hemoglobinopathy. After obtaining approval from the Institutional Review Board, the medical records of the four SCT patients were reviewed and we retrospectively conducted an analysis.